Sacituzumab govitecan significantly extends PFS in advanced breast cancer subset - Healio
6/4/2022 12:00:00 AM2 years 10 months ago
CHICAGO — Sacituzumab govitecan significantly extended PFS vs. single-agent chemotherapy among a heavily pretreated subset of patients with advanced breast cancer subset, according to study results presented during ASCO Annual Meeting.The results also s…
Source/Disclosures Source: Rugo HS, et al. Abstract LBA1001. Presented at: ASCO Annual Meeting; June 3-7, 2022; Chicago. Disclosures: Rugo reports honoraria from Mylan, Puma Biotechnology and Sa… [+7796 chars]
full article...